A Phase 3 interventional study of Sarilumab and Adalimumab in Rheumatoid Arthritis, sponsored by Sanofi. Completed at 86 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-28.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.
Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 6th largest by enrollment, is one of 3 that started in 2015, is one of 9 in phase 3, and was the 14th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:
Sanofi · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 4 · Phase 3 10 · Phase 4 2
First in 2007; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 369 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 88 across the 22 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
36 studies in Arthritis, Rheumatoid by Sanofi: 2 open now, 2 under way, none of them phase 3. Of 34 finished, 14 (41%) have results posted.
Among the 36 studies in Arthritis, Rheumatoid by Sanofi, this one is the 6th largest by enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2015, is one of 9 in phase 3, and was the 24th registered.
Sanofi’s Arthritis, Rheumatoid studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 36 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate that sarilumab monotherapy was superior to adalimumab monotherapy with respect to signs and symptoms as assessed by disease activity score 28 (DAS28)-erythrocyte sedimentation rate (ESR) in participants with active rheumatoid arthritis (RA) who were either intolerant of, or considered inappropriate candidates for continued treatment with methotrexate (MTX), or after at least 12 weeks of continued treatment with MTX, were determined to be inadequate responders.
Secondary Objectives:
To demonstrate that sarilumab monotherapy was superior to adalimumab monotherapy in participants with active RA who were either intolerant of, or considered inappropriate candidates for continued treatment with MTX, or after at least 12 weeks of continued treatment with MTX, were determined to be inadequate responders, with respect to:
Assessment of the safety and tolerability of sarilumab monotherapy (including immunogenicity) throughout the study.
Total study duration was up to 310 weeks: Up to a 4 week screening period, 24 week randomized double-blind treatment phase, 276-week open-label extension, and 6 weeks post-treatment final study visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least 6 of 66 swollen joints and 8 of 68 tender joints, high sensitivity C-reactive protein (hs-CRP) >=8 mg/L or ESR >=28 millimeter per hour (mm/H), and DAS28-ESR greater than (>) 5.1.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adalimumab 40 milligrams (mg) subcutaneous (SC) injection in combination with placebo for sarilumab every 2 weeks (q2w) for 24 weeks during the double-blind (DB) period. The dosing frequency of adalimumab was adjusted to 40 mg every week (qw) dosing in case of participants with inadequate response (less than \[\<\] 20% improvement from baseline in tender joint count \[TJC\] and swollen joint count \[SJC\] for 2 consecutive visits) at or after Week 16 until Week 23. Participants who completed 24 weeks in the DB period had the option to continue in open label extension (OLE) period and received sarilumab 200 mg q2w until commercial availability of sarilumab in their country or up to a maximum of an additional 276 weeks (i.e. up to Week 300).
Drug: Adalimumab · Drug: Placebo (for sarilumab)
Sarilumab 200 mg SC injection in combination with placebo for adalimumab q2w for 24 weeks during the DB period. The dosing frequency of placebo for adalimumab was adjusted to 40 mg qw dosing in case of participants with inadequate response (\<20% improvement from baseline in TJC and SJC for 2 consecutive visits) at or after Week 16 until Week 23. Participants who completed 24 weeks in the DB period had the option to continue in OLE period and received sarilumab 200 mg q2w until commercial availability of sarilumab in their country or up to a maximum of an additional 276 weeks (i.e. up to Week 300).
Drug: Sarilumab · Drug: Placebo (for adalimumab)
Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
Also known as: SAR153191, REGN88
Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
Also known as: Humira
Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24
DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR and RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission. Least square (LS) mean and standard error (SE) at Week 24 were obtained using Mixed-effect model with repeated measures (MMRM) approach.
Time frame: Baseline, Week 24
DB Period: Percentage of Participants Achieving Clinical Remission Score (DAS28-ESR <2.6) at Week 24
DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission. Participants who discontinued treatment prior to Week 24 were analyzed as non-responders.
Time frame: Week 24
DB Period: Percentage of Participants Achieving ACR50 Criteria at Week 24
ACR responses are assessed with a composite rating scale of the ACR that includes 7 variables: TJC (68 joints); SJC (66 joints); levels of an acute phase reactant (C-reactive protein \[CRP\] level); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by Health Assessment Questionnaire - Disability Index \[HAQ-DI\], with scoring range of 0 \[better physical function\] - 3 \[worst physical function\]). ACR50 is defined as achieving at least 50% improvement in both TJC and SJC, and at least 50% improvement in at least 3 of the 5 other assessments of the ACR. Participants were analyzed as non-responders from the time they discontinued treatment.
Time frame: Week 24
DB Period: Percentage of Participants Achieving ACR70 Criteria at Week 24
ACR responses are assessed with a composite rating scale of the ACR that includes 7 variables: TJC (68 joints); SJC (66 joints); levels of an acute phase reactant (CRP level); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by HAQ-DI, with scoring range of 0 \[better physical function\] - 3 \[worst physical function\]). ACR70 was defined as achieving at least 70% improvement in both TJC and SJC, and at least 70% improvement in at least 3 of the 5 other assessments. Participants were analyzed as non-responders from the time they discontinued treatment.
Time frame: Week 24
DB Period: Percentage of Participants Achieving ACR20 Criteria at Week 24
ACR responses are assessed with a composite rating scale of the ACR that includes 7 variables: TJC (68 joints); SJC (66 joints); levels of an acute phase reactant (CRP level); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by HAQ-DI, with scoring range of 0 \[better physical function\] - 3 \[worst physical function\]). ACR20 was defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments. Participants were analyzed as non-responders from the time they discontinued treatment.
Time frame: Week 24
DB Period: Change From Baseline in HAQ-DI at Week 24
Physical function was assessed by HAQ-DI. It consisted of at least 2 or 3 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, ranging from 0 to 3, where 0 = no disability and 3 = unable to do, high-dependency disability. LS mean and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in Short-Form-36 (SF-36) - Physical Component Summary (PCS) Score at Week 24
SF-36 is a generic 36-item questionnaire consisting of 8 sub-scales, measures health-related quality of life (HRQL) in the last 4 weeks covering 2 summary measures: PCS and mental component summary (MCS). PCS with 4 sub-scales: physical function, role limitations due to physical problems, pain, and general health perception; and MCS with 4 sub-scales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a sub-scale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same sub-scale give the sub-scale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Both PCS and MCS range from 0-100 with higher scores indicating better physical and mental health. LS mean and SE at Week 24 by MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 24
The FACIT-F is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0-4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. A total score ranged from 0 to 52, where higher score corresponds to a lower level of fatigue. A positive change from baseline score indicates an improvement. LS mean and SE at Week 24 by MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in SF-36 - Mental Health Component Summary Score at Week 24
SF-36 is a generic 36-item questionnaire consisting of 8 sub-scales, measures HRQL in the last 4 weeks covering 2 summary measures: PCS and MCS. PCS with 4 subscales: physical function, role limitations due to physical problems, pain, and general health perception; and MCS with 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same sub-scale give the sub-scale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Both PCS and MCS range from 0-100 with higher scores indicating better physical and mental health. LS mean and SE at Week 24 by MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in Disease Activity Score for 28 Joints Based on C-Reactive Protein (DAS28-CRP Score) at Week 24
DAS28-CRP is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by high sensitivity C-reactive protein (hs-CRP) in mg/L. The DAS28-CRP score provides a number indicating the current disease activity of the RA. DAS28-CRP total score ranges from 2-10. A DAS28-CRP score above 5.1 means high disease activity, whereas a DAS28-CRP score below 3.2 indicates low disease activity and a DAS28-CRP score below 2.6 means disease remission. LS mean and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Percentage of Participants Achieving Clinical Remission Score (DAS28-CRP <2.6) at Week 24
DAS28-CRP is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by hs-CRP in mg/L. The DAS28-CRP score provides a number indicating the current disease activity of the RA. DAS28-CRP total score ranges from 2-10. A DAS28-CRP score above 5.1 means high disease activity, whereas a DAS28-CRP score below 3.2 indicates low disease activity and a DAS28-CRP score below 2.6 means disease remission. Participants were analyzed as non-responders from the time they discontinued treatment.
Time frame: Week 24
DB Period: Percentage of Participants Achieving Low Disease Activity (DAS28-ESR < 3.2) at Week 24
DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission. Participants were analyzed as non-responders from the time they discontinued treatment.
Time frame: Week 24
DB Period: Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Remission (CDAI ≤2.8) at Week 24
CDAI is a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global assessment of disease activity (in cm), and physician's global assessment of disease activity (in cm). Total score ranges from 0 to 76 with a lower score indicating less disease activity. Participants were analyzed as non-responders from the time they discontinued treatment.
Time frame: Week 24
DB Period: Change From Baseline in CDAI at Week 24
CDAI is a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global assessment of disease activity (in cm), and physician's global assessment of disease activity (VAS in cm). Total score ranges from 0 to 76 with a lower score indicating less disease activity. A negative change in CDAI score indicates an improvement in disease activity and a positive change in score indicates a worsening of disease activity. LS means and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in European Quality of Life-5 Dimension 3 Level (EQ-5D-3L) Scores at Week 24
EQ-5D-3L is a standardized, generic measure of health outcome. EQ-5D was designed for self-completion by participants. EQ-5D was specifically included to address concerns regarding the health economic impact of RA. EQ-5D-3L comprises of 5 questions on mobility, self-care, pain/discomfort, usual activities, and psychological status with 3 possible answers for each item (1=no problem, 2=moderate problems, 3=severe problems). The 5-dimensional 3-level systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-3L-VAS records the participant's self-rated health on a vertical VAS that allows the participants to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable). LS mean and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) at Week 24
RAID is a composite measure of the impact of RA on participants that takes into account 7 domains: pain, functional disability, fatigue, physical and emotional well-being, quality of sleep, and coping. The RAID is calculated based on 7 numerical rating scales (NRS) questions. Each NRS is assessed as a number between 0 and 10 that corresponds to the 7 domains. The values for each of these domains are weighed by participant assessment of relative importance and combined in a single score with a total score range of 0 (not affected, very good) to 10 (most affected). LS mean and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Week 24: Work Days Missed Due to Arthritis
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days missed in the last month by the participant was reported. LS mean and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in WPS-RA at Week 24: Days With Work Productivity Reduced by ≥ 50% Due to Arthritis
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days with reduced productivity by \>= 50% in the last month by the participants was reported. LS mean and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in WPS-RA at Week 24: Arthritis Interference With Work Productivity
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Interference in the last month with work productivity was measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in WPS-RA at Week 24: House Work Days Missed Due to Arthritis
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with no household work in the last month by the participants was reported. LS mean and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in WPS-RA at Week 24: Days With Household Work Productivity Reduced by >= 50% Due to Arthritis
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with reduced household work productivity by \>= 50% in the last month by the participants was reported. LS mean and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in WPS-RA at Week 24: Days With Family/Social/Leisure Activities Missed Due to Arthritis
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days missed of family/social/leisure activities in the last month by the participants was reported. LS mean and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in WPS-RA at Week 24: Days With Outside Help Hired Due to Arthritis
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with outside help hired in the last month by the participant was reported. LS mean and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in WPS-RA at Week 24: RA Interference With Household Work Productivity
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). The RA interference in the last month with household work productivity was measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in Morning Stiffness VAS at Week 24
RA is associated with stiffness of joints, especially in the morning after prolonged stationery state. The degree of stiffness can be an indicator of disease severity. The severity of morning stiffness was assessed on a VAS scale from 0 mm (no problem) to 100 mm (major problem). LS mean and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in Individual ACR Component - TJC and SJC at Week 24
ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& acute phase reactant (hs-CRP and ESR levels). 68 joints were assessed for tenderness (TJC scoring 0-68) and 66 joints for swelling (SJC scoring 0-66). The 66 SJC evaluated the following joints: temporomandibular, sternoclavicular, acromioclavicular, shoulder, elbow, wrist, metacarpophalangeal, interphalangeal of thumb, distal interphalangeal, proximal interphalangeal, knee, ankle mortise, ankle tarsus, metatarsophalangeal, interphalangeal of great toe, and proximal/distal interphalangeal of the toes. The TJC examined hip joints, in addition to the joints assessed for SJC. Increase in number of tender joints/swollen joints indicated severity. LS mean and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in Individual ACR Component - Physician Global VAS, Participant Global VAS and Pain VAS at Week 24
ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& acute phase reactant (hs-CRP and ESR levels). Physician global VAS \& participant global VAS was done on 100 mm horizontal anchored VAS, ranging from 0 "no arthritis activity" to 100 "maximal arthritis activity" and Pain VAS on 100 mm VAS, ranging from 0 "no pain" to 100 "worst pain". LS mean and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in Individual ACR Component - CRP Level at Week 24
ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& acute phase reactant (hs-CRP and ESR levels). An elevated CRP level is considered a non-specific "marker" for RA. A decrease indicates improvement. LS mean and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Change From Baseline in Individual ACR Component- ESR Level at Week 24
ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& acute phase reactant (hs-CRP and ESR levels). The ESR is a blood test that can reveal inflammatory activity. Inflammation can cause the cells to clump together. The farther the red blood cells have descended, the greater the inflammatory response. LS mean and SE at Week 24 were obtained using MMRM approach.
Time frame: Baseline, Week 24
DB Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Adverse event (AE) was defined as any untoward medical occurrence in participant who received investigational medicinal product (IMP) and did not necessarily had to have causal relationship with treatment. All reported AEs are TEAEs developed/worsened during 'on treatment period' (time from first dose of study drug up to day before first dose of open-label treatment for participants who completed 24-week randomized//DB treatment). SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event.
Time frame: From Week 0 to Week 24
OLE Period: Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events
AE was defined as any untoward medical occurrence in participant who received IMP and did not necessarily had to have causal relationship with treatment. All reported AEs are TEAEs developed/worsened during 'on treatment period' (from end of week 24 \[Baseline of OLE Period\] up to last dose in OLE period + 6 weeks \[follow-up\], regardless of unplanned intermittent discontinuations). SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event.
Time frame: From end of Week 24 (Baseline of OLE Period) up to last dose in OLE + 6 weeks of follow up (i.e. up to Week 306)
DB Period: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) - Hematological Parameters
Criteria for potentially clinically significant laboratory abnormalities included: * Hemoglobin (Hb): less than or equal to (\<=) 115 grams per liter (g/L) (Male), \<= 95 g/L (Female); greater than or equal to (\>=) 185 g/L (18.5 g/dL) (Male), \>= 165 g/L (16.5 g/dL) (Female); Decrease From Baseline (DFB) = 20 g/L (2 g/dL). * Hematocrit: \<= 0.37 volume/volume (v/v) (Male); \<= 0.32 v/v (F); \>= 0.55 v/v (Male); \>= 0.5 v/v (Female). * Red Blood Cells (RBCs): \>=6 Tera/ liter (L). * Platelets: \< 50 Giga/L, 50 - 100 Giga/L, \>= 700 Giga/L. * White blood cells (WBC): \< 3.0 Giga/L (Non-Black); \< 2.0 Giga/L (Black), \>= 16.0 Giga/L. * Neutrophils: \< 1.0 Giga/L, \< 1.5 Giga/L (Non-Black); \< 1.0 Giga/L (Black). * Lymphocytes: \< 0.5 Giga/L, \>= 0.5 Giga/L - lower limit of normal (LLN), \> 4.0 Giga/L. * Monocytes: \> 0.7 Giga/L. * Basophils: \> 0.1 Giga/L. * Eosinophils: \> 0.5 Giga/L or \> upper limit of normal (ULN) (if ULN \>= 0.5 Giga/L).
Time frame: From Week 0 to Week 24
OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Hematological Parameters
Criteria for potentially clinically significant laboratory abnormalities included: * Hb: \<=115 g/L (Male), \<= 95 g/L (Female); \>=185 g/L (18.5 g/dL) (Male), \>= 165 g/L (16.5 g/dL) (Female); DFB \>= 20 g/L (2 g/dL). * Hematocrit: \<= 0.37 v/v (Male); \<= 0.32 v/v (Female); \>= 0.55 v/v (Male); \>= 0.5 v/v (Female). * RBCs: \>=6 Tera/ L. * Platelets: \< 50 Giga/L, \>=50 - 100 Giga/L, \>= 700 Giga/L. * WBC: \< 3.0 Giga/L (Non-Black); \< 2.0 Giga/L (Black), \>= 16.0 Giga/L. * Neutrophils: \< 1.0 Giga/L, \< 1.5 Giga/L (Non-Black); \< 1.0 Giga/L (Black). * Lymphocytes: \< 0.5 Giga/L, \>= 0.5 Giga/L - LLN, \> 4.0 Giga/L. * Monocytes: \> 0.7 Giga/L. * Basophils: \> 0.1 Giga/L. * Eosinophils: \> 0.5 Giga/L or \> ULN (if ULN \>= 0.5 Giga/L).
Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300
DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Liver Function Tests
Criteria for potentially clinically significant abnormalities: * Alanine Aminotransferase (ALT): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN. * Aspartate aminotransferase (AST): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN. * Alkaline phosphatase: \>1.5 ULN. * Total bilirubin (TBILI): \>1.5 ULN; \>2 ULN. * Conjugated bilirubin (CBILI): \>1.5 ULN. * Unconjugated bilirubin: \>1.5 ULN, \>2 ULN. * ALT \>3 ULN and TBILI \>2 ULN. * CBILI \>35% TBILI and TBILI \>1.5 ULN. * Albumin: \<=25 g/L.
Time frame: From Week 0 to Week 24
OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Liver Function Tests
Criteria for potentially clinically significant abnormalities: * ALT: \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN. * AST: \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN. * Alkaline phosphatase: \>1.5 ULN. * TBILI: \>1.5 ULN; \>2 ULN. * CBILI: \>1.5 ULN. * Unconjugated bilirubin: \>1.5 ULN, \>2 ULN. * ALT \>3 ULN and TBILI \>2 ULN. * CBILI \>35% TBILI and TBILI \>1.5 ULN. * Albumin: \<=25 g/L.
Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300
DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Metabolic Parameters
Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 millimole/liter (mmol/L) and \<LLN; \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]). * Hemoglobin A1c (HbA1c): \>8%. * Total cholesterol: \>=6.2 mmol/L; \>=7.74 mmol/L. * LDL cholesterol: \>=4.1 mmol/L; \>=4.9 mmol/L. * Triglycerides: \>=4.6 mmol/L; \>=5.6 mmol/L.
Time frame: From Week 0 to Week 24
OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Metabolic Parameters
Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \<LLN; \>=11.1 mmol/L (unfas) or \>=7 mmol/L (fas). * HbA1c: \>8%. * Total cholesterol: \>=6.2 mmol/L; \>=7.74 mmol/L. * LDL cholesterol: \>=4.1 mmol/L; \>=4.9 mmol/L. * Triglycerides: \>=4.6 mmol/L; \>=5.6 mmol/L.
Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300
DB Period: Number of Participants With Different Post-baseline Categories of High-density Lipoprotein (HDL)
Number of participants with different post-baseline status of HDL: \< 40 mg/dL, 40 - \< 60 mg/dL, \>= 60 mg/dL, is reported here.
Time frame: From Week 0 to Week 24
OLE Period: Number of Participants With Different Post-baseline Categories of High-density Lipoprotein
Number of participants with different post-baseline status of HDL: \< 40 mg/dL, 40 - \< 60 mg/dL, \>=60 mg/dL, is reported here.
Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300
DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Renal Function
Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromol/L (adults); \>=30% change from baseline, \>=100% change from baseline. * Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \<60 mL/min; \>=60 to \<90 mL/min. * Blood urea nitrogen: \>=17 mmol/L. * Uric acid: \<120 micromol/L; \>408 micromol/L.
Time frame: From Week 0 to Week 24
OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Renal Function
Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromol/L (adults); \>=30% change from baseline, \>=100% change from baseline. * Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \<60 mL/min; \>=60 to \<90 mL/min. * Blood urea nitrogen: \>=17 mmol/L. * Uric acid: \<120 micromol/L; \>408 micromol/L.
Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300
DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Urinalysis
Criteria with potentially clinically significant urine abnormalities: pH: \<= 4.6; pH: \>= 8.0.
Time frame: From Week 0 to Week 24
OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Urinalysis
Criteria with potentially clinically significant urine abnormalities: pH: \<= 4.6; pH: \>= 8.0.
Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300
DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Electrolytes
Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 mmol/L; \>=160 mmol/L. * Potassium: \<3 mmol/L; \>=5.5 mmol/L. * Chloride: \<80 mmol/L; \>115 mmol/L.
Time frame: From Week 0 to Week 24
OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Electrolytes
Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 mmol/L; \>=160 mmol/L. * Potassium: \<3 mmol/L; \>=5.5 mmol/L. * Chloride: \<80 mmol/L; \>115 mmol/L.
Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300
DB Period: Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
Criteria for potentially clinically significant ECG abnormalities: * Heart rate (HR): \<50 beats per minute (bpm); \<50 bpm and DFB \>=20 bpm; \<40 bpm; \<40 bpm and DFB \>=20 bpm; \<30 bpm; \<30 bpm and DFB \>=20 bpm; \>90 bpm; \>=90 bpm and increase from baseline (IFB) \>=20 bpm; \>100 bpm; \>=100 bpm and IFB \>=20 bpm; \>120 bpm; \>=120 bpm and IFB \>=20 bpm. * PR Interval: \>200 millisecond (ms); \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25%. * QRS Interval: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25%. * QT Interval: \>500 ms. * QTc Bazett (QTc B): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms. * QTc Fridericia (QTc F): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms.
Time frame: From Week 0 to Week 24
OLE Period: Number of Participants With Potentially Clinically Significant Electrocardiogram Abnormalities
Criteria for potentially clinically significant ECG abnormalities: * HR: \<50 bpm; \<50 bpm and DFB \>=20 bpm; \<40 bpm; \<40 bpm and DFB \>=20 bpm; \<30 bpm; \<30 bpm and DFB \>=20 bpm; \>90 bpm; \>=90 bpm and IFB \>=20 bpm; \>100 bpm; \>=100 bpm and IFB \>=20 bpm; \>120 bpm; \>=120 bpm and IFB \>=20 bpm. * PR Interval: \>200 ms; \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25%. * QRS Interval: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25%. * QT Interval: \>500 ms. * QTc B: \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms. * QTc F: \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms.
Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300
DB Period: Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities
Criteria for potentially clinically significant vital sign abnormalities: Systolic blood pressure (SBP) supine: \<=95 mmHg and DFB\>=20 mmHg; \>=160 mmHg and IFB \>=20 mmHg. Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg. SBP (Orthostatic): \<=-20 mmHg. DBP (Orthostatic): \<=-10 mmHg. HR supine: \<=50 bpm and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm. Weight: \>=5% DFB; \>=5% IFB.
Time frame: From Week 0 to Week 24
OLE Period: Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities
Criteria for potentially clinically significant vital sign abnormalities: SBP supine: \<=95 mmHg and DFB \>=20 mmHg; \>=160 mmHg and IFB \>=20 mmHg. DBP supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg. SBP (Orthostatic): \<=-20 mmHg. DBP (Orthostatic): \<=-10 mmHg. HR supine: \<=50 bpm and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm. Weight: \>=5% DFB; \>=5% IFB.
Time frame: From end of Week 24 (Baseline of OLE Period) up to Week 300
DB Period: Number of Participants With Treatment-emergent and Treatment-boosted Anti-drug Antibody (ADA) Response
Anti-drug antibody response was categorized as: Treatment emergent and Treatment-boosted. Treatment emergent ADAs was defined as a participant with no positive assay response at baseline but with a positive assay response during the TEAE period. Treatment boosted ADAs: defined as participants with a positive ADA assay response at baseline and with at least a 4-fold increase in titer compared to baseline during the TEAE period. TEAE period: time from first dose of study drug up to day before first dose of open-label treatment for participants who completed 24-week randomized/DB treatment.
Time frame: From Week 0 to Week 24
Number of Participants With Treatment-emergent and Treatment-boosted Anti-drug Antibody Response During Entire Treatment-emergent Adverse Event Period
Anti-drug antibody response was categorized as: Treatment emergent and Treatment-boosted. Treatment emergent ADAs was defined as a participant with no positive assay response at baseline but with a positive assay response during the entire TEAE period. Treatment boosted ADAs: defined as participants with a positive ADA assay response at baseline and with at least a 4-fold increase in titer compared to baseline during the entire TEAE period. Entire TEAE period: last OLE dose - first DB dose date + 6 weeks (follow-up), regardless of unplanned intermittent discontinuations.
Time frame: From Week 0 up to last dose in OLE + 6 weeks of follow-up (i.e. up to Week 306)
DB Period: Pharmacokinetics: Serum Trough (Pre-dose) Concentrations of Functional Sarilumab
Data for this outcome measure was not planned to be collected and analyzed for "Adalimumab 40 mg/Sarilumab 200 mg" arm.
Time frame: Pre-dose at Week 0 (Baseline), 2, 4, 12, 16, 20, and 24
OLE Period: Pharmacokinetics: Serum Trough (Pre-dose) Concentrations of Functional Sarilumab
Time frame: Pre-dose at Week 24 (Baseline of OLE period), 36, 48, 60, 84, 108, 132, 156, 180, 204, 228, 252, 276, 300 and 306
The study was conducted at 86 centers in 15 countries. A total of 540 participants were involved in the study from 28 January 2015 to 29-December-2020, of whom 369 participants were randomized and 171 were screen failures. Screen failures were mainly due to exclusion criteria met and inclusion criteria not met.
| Milestone | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| Started | 185 | 184 |
| Treated | 184 | 184 |
| Completed | 156 | 165 |
| Not completed | 29 | 19 |
| Withdrew: Adverse event | 15 | 11 |
| Withdrew: Lack of efficacy | 4 | 2 |
| Withdrew: Poor compliance to protocol | 3 | 1 |
| Withdrew: Randomized but not treated | 1 | 0 |
| Withdrew: Other than specified above | 6 | 5 |
| Milestone | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| Started | 155 | 165 |
| Completed | 108 | 120 |
| Not completed | 47 | 45 |
| Withdrew: Adverse event | 20 | 23 |
| Withdrew: Lack of efficacy | 2 | 6 |
| Withdrew: Poor compliance to protocol | 5 | 1 |
| Withdrew: Other unspecified | 20 | 15 |
DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR and RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission. Least square (LS) mean and standard error (SE) at Week 24 were obtained using Mixed-effect model with repeated measures (MMRM) approach.
| units on a scale | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 | -2.20 ± 0.106 | -3.28 ± 0.105 |
DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission. Participants who discontinued treatment prior to Week 24 were analyzed as non-responders.
| percentage of participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Percentage of Participants Achieving Clinical Remission Score (DAS28-ESR <2.6) at Week 24 | 7.0 | 26.6 |
ACR responses are assessed with a composite rating scale of the ACR that includes 7 variables: TJC (68 joints); SJC (66 joints); levels of an acute phase reactant (C-reactive protein \[CRP\] level); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by Health Assessment Questionnaire - Disability Index \[HAQ-DI\], with scoring range of 0 \[better physical function\] - 3 \[worst physical function\]). ACR50 is defined as achieving at least 50% improvement in both TJC and SJC, and at least 50% improvement in at least 3 of the 5 other assessments of the ACR. Participants were analyzed as non-responders from the time they discontinued treatment.
| percentage of participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Percentage of Participants Achieving ACR50 Criteria at Week 24 | 29.7 | 45.7 |
ACR responses are assessed with a composite rating scale of the ACR that includes 7 variables: TJC (68 joints); SJC (66 joints); levels of an acute phase reactant (CRP level); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by HAQ-DI, with scoring range of 0 \[better physical function\] - 3 \[worst physical function\]). ACR70 was defined as achieving at least 70% improvement in both TJC and SJC, and at least 70% improvement in at least 3 of the 5 other assessments. Participants were analyzed as non-responders from the time they discontinued treatment.
| percentage of participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Percentage of Participants Achieving ACR70 Criteria at Week 24 | 11.9 | 23.4 |
ACR responses are assessed with a composite rating scale of the ACR that includes 7 variables: TJC (68 joints); SJC (66 joints); levels of an acute phase reactant (CRP level); participant's assessment of pain (measured on 0 \[no pain\]-100 mm \[worst pain\] VAS); participant's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); physician's global assessment of disease activity (measured on 0 \[no arthritis activity\]-100 mm \[maximal arthritis activity\] VAS); participant's assessment of physical function (measured by HAQ-DI, with scoring range of 0 \[better physical function\] - 3 \[worst physical function\]). ACR20 was defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments. Participants were analyzed as non-responders from the time they discontinued treatment.
| percentage of participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Percentage of Participants Achieving ACR20 Criteria at Week 24 | 58.4 | 71.7 |
Physical function was assessed by HAQ-DI. It consisted of at least 2 or 3 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, ranging from 0 to 3, where 0 = no disability and 3 = unable to do, high-dependency disability. LS mean and SE at Week 24 were obtained using MMRM approach.
| units on a scale | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in HAQ-DI at Week 24 | -0.43 ± 0.045 | -0.61 ± 0.045 |
SF-36 is a generic 36-item questionnaire consisting of 8 sub-scales, measures health-related quality of life (HRQL) in the last 4 weeks covering 2 summary measures: PCS and mental component summary (MCS). PCS with 4 sub-scales: physical function, role limitations due to physical problems, pain, and general health perception; and MCS with 4 sub-scales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a sub-scale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same sub-scale give the sub-scale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Both PCS and MCS range from 0-100 with higher scores indicating better physical and mental health. LS mean and SE at Week 24 by MMRM approach.
| units on a scale | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in Short-Form-36 (SF-36) - Physical Component Summary (PCS) Score at Week 24 | 6.09 ± 0.555 | 8.74 ± 0.555 |
The FACIT-F is a 13-item questionnaire assessing fatigue where participants scored each item on a 5-point scale (0-4): 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. A total score ranged from 0 to 52, where higher score corresponds to a lower level of fatigue. A positive change from baseline score indicates an improvement. LS mean and SE at Week 24 by MMRM approach.
| units on a scale | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 24 | 8.41 ± 0.709 | 10.18 ± 0.701 |
SF-36 is a generic 36-item questionnaire consisting of 8 sub-scales, measures HRQL in the last 4 weeks covering 2 summary measures: PCS and MCS. PCS with 4 subscales: physical function, role limitations due to physical problems, pain, and general health perception; and MCS with 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same sub-scale give the sub-scale scores, which are transformed into a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Both PCS and MCS range from 0-100 with higher scores indicating better physical and mental health. LS mean and SE at Week 24 by MMRM approach.
| units on a scale | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in SF-36 - Mental Health Component Summary Score at Week 24 | 6.83 ± 0.774 | 7.86 ± 0.773 |
DAS28-CRP is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by high sensitivity C-reactive protein (hs-CRP) in mg/L. The DAS28-CRP score provides a number indicating the current disease activity of the RA. DAS28-CRP total score ranges from 2-10. A DAS28-CRP score above 5.1 means high disease activity, whereas a DAS28-CRP score below 3.2 indicates low disease activity and a DAS28-CRP score below 2.6 means disease remission. LS mean and SE at Week 24 were obtained using MMRM approach.
| units on a scale | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in Disease Activity Score for 28 Joints Based on C-Reactive Protein (DAS28-CRP Score) at Week 24 | -1.97 ± 0.094 | -2.86 ± 0.093 |
DAS28-CRP is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by hs-CRP in mg/L. The DAS28-CRP score provides a number indicating the current disease activity of the RA. DAS28-CRP total score ranges from 2-10. A DAS28-CRP score above 5.1 means high disease activity, whereas a DAS28-CRP score below 3.2 indicates low disease activity and a DAS28-CRP score below 2.6 means disease remission. Participants were analyzed as non-responders from the time they discontinued treatment.
| percentage of participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Percentage of Participants Achieving Clinical Remission Score (DAS28-CRP <2.6) at Week 24 | 13.5 | 34.2 |
DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); GH assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission. Participants were analyzed as non-responders from the time they discontinued treatment.
| percentage of participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Percentage of Participants Achieving Low Disease Activity (DAS28-ESR < 3.2) at Week 24 | 14.1 | 42.9 |
CDAI is a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global assessment of disease activity (in cm), and physician's global assessment of disease activity (in cm). Total score ranges from 0 to 76 with a lower score indicating less disease activity. Participants were analyzed as non-responders from the time they discontinued treatment.
| percentage of participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Remission (CDAI ≤2.8) at Week 24 | 2.7 | 7.1 |
CDAI is a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global assessment of disease activity (in cm), and physician's global assessment of disease activity (VAS in cm). Total score ranges from 0 to 76 with a lower score indicating less disease activity. A negative change in CDAI score indicates an improvement in disease activity and a positive change in score indicates a worsening of disease activity. LS means and SE at Week 24 were obtained using MMRM approach.
| units on a scale | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in CDAI at Week 24 | -25.20 ± 0.842 | -28.94 ± 0.834 |
EQ-5D-3L is a standardized, generic measure of health outcome. EQ-5D was designed for self-completion by participants. EQ-5D was specifically included to address concerns regarding the health economic impact of RA. EQ-5D-3L comprises of 5 questions on mobility, self-care, pain/discomfort, usual activities, and psychological status with 3 possible answers for each item (1=no problem, 2=moderate problems, 3=severe problems). The 5-dimensional 3-level systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-3L-VAS records the participant's self-rated health on a vertical VAS that allows the participants to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable). LS mean and SE at Week 24 were obtained using MMRM approach.
| units on a scale | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| EQ-5D Single index utility score | 0.26 ± 0.019 | 0.32 ± 0.019 |
| EQ-5D VAS | 19.94 ± 1.720 | 24.22 ± 1.686 |
RAID is a composite measure of the impact of RA on participants that takes into account 7 domains: pain, functional disability, fatigue, physical and emotional well-being, quality of sleep, and coping. The RAID is calculated based on 7 numerical rating scales (NRS) questions. Each NRS is assessed as a number between 0 and 10 that corresponds to the 7 domains. The values for each of these domains are weighed by participant assessment of relative importance and combined in a single score with a total score range of 0 (not affected, very good) to 10 (most affected). LS mean and SE at Week 24 were obtained using MMRM approach.
| units on a scale | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) at Week 24 | -2.30 ± 0.168 | -3.08 ± 0.168 |
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days missed in the last month by the participant was reported. LS mean and SE at Week 24 were obtained using MMRM approach.
| days | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Week 24: Work Days Missed Due to Arthritis | 0.05 ± 0.611 | -0.28 ± 0.547 |
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of work days with reduced productivity by \>= 50% in the last month by the participants was reported. LS mean and SE at Week 24 were obtained using MMRM approach.
| days | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in WPS-RA at Week 24: Days With Work Productivity Reduced by ≥ 50% Due to Arthritis | -3.50 ± 0.525 | -3.74 ± 0.456 |
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Interference in the last month with work productivity was measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 24 were obtained using MMRM approach.
| units on a scale | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in WPS-RA at Week 24: Arthritis Interference With Work Productivity | -2.510 ± 0.3470 | -2.919 ± 0.3073 |
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with no household work in the last month by the participants was reported. LS mean and SE at Week 24 were obtained using MMRM approach.
| days | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in WPS-RA at Week 24: House Work Days Missed Due to Arthritis | -4.22 ± 0.405 | -5.49 ± 0.400 |
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with reduced household work productivity by \>= 50% in the last month by the participants was reported. LS mean and SE at Week 24 were obtained using MMRM approach.
| days | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in WPS-RA at Week 24: Days With Household Work Productivity Reduced by >= 50% Due to Arthritis | -4.87 ± 0.451 | -6.70 ± 0.445 |
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days missed of family/social/leisure activities in the last month by the participants was reported. LS mean and SE at Week 24 were obtained using MMRM approach.
| days | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in WPS-RA at Week 24: Days With Family/Social/Leisure Activities Missed Due to Arthritis | -3.33 ± 0.376 | -4.14 ± 0.371 |
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). Number of days with outside help hired in the last month by the participant was reported. LS mean and SE at Week 24 were obtained using MMRM approach.
| days | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in WPS-RA at Week 24: Days With Outside Help Hired Due to Arthritis | -2.57 ± 0.401 | -3.43 ± 0.398 |
The WPS-RA is a validated questionnaire that evaluates productivity limitations within work and within home associated with RA over the previous month. The questionnaire is interviewer-administered and based on participant self-report. It contains 9 questions addressing employment status (1 item), productivity at work (3 items), and within and outside the home (5 items). The RA interference in the last month with household work productivity was measured on a scale that ranges from 0 (no interference) to 10 (complete interference). LS mean and SE at Week 24 were obtained using MMRM approach.
| units on a scale | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in WPS-RA at Week 24: RA Interference With Household Work Productivity | -2.605 ± 0.2110 | -3.276 ± 0.2099 |
RA is associated with stiffness of joints, especially in the morning after prolonged stationery state. The degree of stiffness can be an indicator of disease severity. The severity of morning stiffness was assessed on a VAS scale from 0 mm (no problem) to 100 mm (major problem). LS mean and SE at Week 24 were obtained using MMRM approach.
| mm | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in Morning Stiffness VAS at Week 24 | -29.29 ± 1.970 | -35.08 ± 1.947 |
ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& acute phase reactant (hs-CRP and ESR levels). 68 joints were assessed for tenderness (TJC scoring 0-68) and 66 joints for swelling (SJC scoring 0-66). The 66 SJC evaluated the following joints: temporomandibular, sternoclavicular, acromioclavicular, shoulder, elbow, wrist, metacarpophalangeal, interphalangeal of thumb, distal interphalangeal, proximal interphalangeal, knee, ankle mortise, ankle tarsus, metatarsophalangeal, interphalangeal of great toe, and proximal/distal interphalangeal of the toes. The TJC examined hip joints, in addition to the joints assessed for SJC. Increase in number of tender joints/swollen joints indicated severity. LS mean and SE at Week 24 were obtained using MMRM approach.
| joints | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| TJC | -16.45 ± 0.781 | -18.23 ± 0.772 |
| SJC | -12.20 ± 0.450 | -13.44 ± 0.444 |
ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& acute phase reactant (hs-CRP and ESR levels). Physician global VAS \& participant global VAS was done on 100 mm horizontal anchored VAS, ranging from 0 "no arthritis activity" to 100 "maximal arthritis activity" and Pain VAS on 100 mm VAS, ranging from 0 "no pain" to 100 "worst pain". LS mean and SE at Week 24 were obtained using MMRM approach.
| mm | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| Physician global VAS | -37.80 ± 1.431 | -45.33 ± 1.414 |
| Participant global VAS | -24.82 ± 1.752 | -33.30 ± 1.731 |
| Pain VAS | -27.41 ± 1.802 | -36.19 ± 1.776 |
ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& acute phase reactant (hs-CRP and ESR levels). An elevated CRP level is considered a non-specific "marker" for RA. A decrease indicates improvement. LS mean and SE at Week 24 were obtained using MMRM approach.
| mg/L | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in Individual ACR Component - CRP Level at Week 24 | -2.91 ± 1.461 | -17.01 ± 1.431 |
ACR components were: TJC, SJC, physician global VAS, participant global VAS, pain VAS, HAQ-DI \& acute phase reactant (hs-CRP and ESR levels). The ESR is a blood test that can reveal inflammatory activity. Inflammation can cause the cells to clump together. The farther the red blood cells have descended, the greater the inflammatory response. LS mean and SE at Week 24 were obtained using MMRM approach.
| mm/hr | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| DB Period: Change From Baseline in Individual ACR Component- ESR Level at Week 24 | -12.74 ± 1.398 | -32.11 ± 1.388 |
Adverse event (AE) was defined as any untoward medical occurrence in participant who received investigational medicinal product (IMP) and did not necessarily had to have causal relationship with treatment. All reported AEs are TEAEs developed/worsened during 'on treatment period' (time from first dose of study drug up to day before first dose of open-label treatment for participants who completed 24-week randomized//DB treatment). SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| TEAEs | 117 | 118 |
| SAEs | 13 | 9 |
AE was defined as any untoward medical occurrence in participant who received IMP and did not necessarily had to have causal relationship with treatment. All reported AEs are TEAEs developed/worsened during 'on treatment period' (from end of week 24 \[Baseline of OLE Period\] up to last dose in OLE period + 6 weeks \[follow-up\], regardless of unplanned intermittent discontinuations). SAEs were AEs resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or a medically important event.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| TEAE | 135 | 143 |
| SAE | 31 | 25 |
Criteria for potentially clinically significant laboratory abnormalities included: * Hemoglobin (Hb): less than or equal to (\<=) 115 grams per liter (g/L) (Male), \<= 95 g/L (Female); greater than or equal to (\>=) 185 g/L (18.5 g/dL) (Male), \>= 165 g/L (16.5 g/dL) (Female); Decrease From Baseline (DFB) = 20 g/L (2 g/dL). * Hematocrit: \<= 0.37 volume/volume (v/v) (Male); \<= 0.32 v/v (F); \>= 0.55 v/v (Male); \>= 0.5 v/v (Female). * Red Blood Cells (RBCs): \>=6 Tera/ liter (L). * Platelets: \< 50 Giga/L, 50 - 100 Giga/L, \>= 700 Giga/L. * White blood cells (WBC): \< 3.0 Giga/L (Non-Black); \< 2.0 Giga/L (Black), \>= 16.0 Giga/L. * Neutrophils: \< 1.0 Giga/L, \< 1.5 Giga/L (Non-Black); \< 1.0 Giga/L (Black). * Lymphocytes: \< 0.5 Giga/L, \>= 0.5 Giga/L - lower limit of normal (LLN), \> 4.0 Giga/L. * Monocytes: \> 0.7 Giga/L. * Basophils: \> 0.1 Giga/L. * Eosinophils: \> 0.5 Giga/L or \> upper limit of normal (ULN) (if ULN \>= 0.5 Giga/L).
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| Hb:<=115 g/L, <=95 g/L | 12 | 7 |
| Hb: >=185 g/L, >=165 g/L | 0 | 1 |
| Hb: DFB >=20 g/L | 5 | 5 |
| Hematocrit: <= 0.37 v/v; <=0.32 v/v | 21 | 10 |
| Hematocrit: >=0.55 v/v; >=0.5 v/v | 1 | 3 |
| RBCs: >=6 Tera/L | 0 | 1 |
| Platelets: < 50 Giga/L | 0 | 1 |
| Platelets: 50 - 100 Giga/L | 0 | 0 |
| Platelets: >= 700 Giga/L | 1 | 0 |
| WBC: < 3.0 Giga/L (Non-Black); < 2.0 Giga/L (Black) | 1 | 32 |
| WBC: >= 16.0 Giga/L | 8 | 5 |
| Neutrophils: < 1.0 Giga/L | 2 | 19 |
| Neutrophils: < 1.5 Giga/L (Non-Black); < 1.0 Giga/L (Black) | 7 | 50 |
| Lymphocytes: < 0.5 Giga/L | 2 | 2 |
| Lymphocytes: >= 0.5 Giga/L - LLN | 8 | 21 |
| Lymphocytes: > 4.0 Giga/L | 17 | 6 |
| Monocytes: > 0.7 Giga/L | 46 | 38 |
| Basophils: > 0.1 Giga/L | 53 | 37 |
| Eosinophils: > 0.5 Giga/L or > ULN (if ULN >= 0.5 Giga/L) | 4 | 9 |
Criteria for potentially clinically significant laboratory abnormalities included: * Hb: \<=115 g/L (Male), \<= 95 g/L (Female); \>=185 g/L (18.5 g/dL) (Male), \>= 165 g/L (16.5 g/dL) (Female); DFB \>= 20 g/L (2 g/dL). * Hematocrit: \<= 0.37 v/v (Male); \<= 0.32 v/v (Female); \>= 0.55 v/v (Male); \>= 0.5 v/v (Female). * RBCs: \>=6 Tera/ L. * Platelets: \< 50 Giga/L, \>=50 - 100 Giga/L, \>= 700 Giga/L. * WBC: \< 3.0 Giga/L (Non-Black); \< 2.0 Giga/L (Black), \>= 16.0 Giga/L. * Neutrophils: \< 1.0 Giga/L, \< 1.5 Giga/L (Non-Black); \< 1.0 Giga/L (Black). * Lymphocytes: \< 0.5 Giga/L, \>= 0.5 Giga/L - LLN, \> 4.0 Giga/L. * Monocytes: \> 0.7 Giga/L. * Basophils: \> 0.1 Giga/L. * Eosinophils: \> 0.5 Giga/L or \> ULN (if ULN \>= 0.5 Giga/L).
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| Hb:<=115 g/L, <=95 g/L | 8 | 5 |
| Hb: >=185 g/L, >=165 g/L | 3 | 3 |
| Hb: DFB >=20 g/L | 13 | 13 |
| Hematocrit: <= 0.37 v/v; <=0.32 v/v | 12 | 14 |
| Hematocrit: >=0.55 v/v; >=0.5 v/v | 5 | 8 |
| RBCs: >=6 Tera/L | 3 | 2 |
| Platelets: < 50 Giga/L | 0 | 0 |
| Platelets: >=50 - 100 Giga/L | 4 | 4 |
| Platelets: >= 700 Giga/L | 2 | 1 |
| WBC: < 3.0 Giga/L (Non-Black); < 2.0 Giga/L (Black) | 34 | 46 |
| WBC: >= 16.0 Giga/L | 11 | 7 |
| Neutrophils: < 1.0 Giga/L | 24 | 25 |
| Neutrophils: < 1.5 Giga/L (Non-Black); < 1.0 Giga/L (Black) | 62 | 69 |
| Lymphocytes: < 0.5 Giga/L | 2 | 3 |
| Lymphocytes: >= 0.5 Giga/L - LLN | 28 | 42 |
| Lymphocytes: > 4.0 Giga/L | 15 | 7 |
| Monocytes: > 0.7 Giga/L | 48 | 43 |
| Basophils: > 0.1 Giga/L | 78 | 70 |
| Eosinophils: > 0.5 Giga/L or > ULN (if ULN >= 0.5 Giga/L) | 11 | 14 |
Criteria for potentially clinically significant abnormalities: * Alanine Aminotransferase (ALT): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN. * Aspartate aminotransferase (AST): \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN. * Alkaline phosphatase: \>1.5 ULN. * Total bilirubin (TBILI): \>1.5 ULN; \>2 ULN. * Conjugated bilirubin (CBILI): \>1.5 ULN. * Unconjugated bilirubin: \>1.5 ULN, \>2 ULN. * ALT \>3 ULN and TBILI \>2 ULN. * CBILI \>35% TBILI and TBILI \>1.5 ULN. * Albumin: \<=25 g/L.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| ALT >1 ULN and <=1.5 ULN | 22 | 36 |
| ALT >1.5 ULN and <=3 ULN | 17 | 26 |
| ALT >3 ULN and <=5 ULN | 3 | 5 |
| ALT >5 ULN and <=10 ULN | 1 | 1 |
| ALT >10 ULN and <=20 ULN | 1 | 0 |
| ALT >20 ULN | 0 | 0 |
| AST >1 ULN and <=1.5 ULN | 16 | 22 |
| AST >1.5 ULN and <=3 ULN | 7 | 13 |
| AST >3 ULN and <=5 ULN | 3 | 2 |
| AST >5 ULN and <=10 ULN | 0 | 0 |
| AST >10 ULN and <=20 ULN | 1 | 0 |
| AST >20 ULN | 0 | 0 |
| Alkaline Phosphatase >1.5 ULN | 6 | 2 |
| TBILI >1.5 ULN | 1 | 7 |
| TBILI >2 ULN | 0 | 2 |
| CBILI >1.5 ULN | 0 | 0 |
| Unconjugated Bilirubin >1.5 ULN | 5 | 13 |
| Unconjugated Bilirubin >2 ULN | 1 | 7 |
| ALT> 3 ULN and TBILI >2 ULN | 0 | 0 |
| CBILI >35% TBILI and TBILI >1.5 ULN | 0 | 0 |
| Albumin <=25 g/L | 0 | 0 |
Criteria for potentially clinically significant abnormalities: * ALT: \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN. * AST: \>1 ULN and \<=1.5 ULN; \>1.5 ULN and \<=3 ULN; \>3 ULN and \<=5 ULN; \>5 ULN and \<=10 ULN; \>10 ULN and \<=20 ULN; \>20 ULN. * Alkaline phosphatase: \>1.5 ULN. * TBILI: \>1.5 ULN; \>2 ULN. * CBILI: \>1.5 ULN. * Unconjugated bilirubin: \>1.5 ULN, \>2 ULN. * ALT \>3 ULN and TBILI \>2 ULN. * CBILI \>35% TBILI and TBILI \>1.5 ULN. * Albumin: \<=25 g/L.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| ALT >1 ULN and <=1.5 ULN | 41 | 36 |
| ALT >1.5 ULN and <=3 ULN | 31 | 34 |
| ALT >3 ULN and <=5 ULN | 11 | 10 |
| ALT >5 ULN and <=10 ULN | 1 | 6 |
| ALT >10 ULN and <=20 ULN | 0 | 2 |
| ALT >20 ULN | 1 | 1 |
| AST >1 ULN and <=1.5 ULN | 25 | 39 |
| AST >1.5 ULN and <=3 ULN | 23 | 17 |
| AST >3 ULN and <=5 ULN | 2 | 7 |
| AST >5 ULN and <=10 ULN | 2 | 2 |
| AST >10 ULN and <=20 ULN | 0 | 0 |
| AST >20 ULN | 0 | 1 |
| Alkaline Phosphatase >1.5 ULN | 0 | 1 |
| TBILI >1.5 ULN | 11 | 6 |
| TBILI >2 ULN | 3 | 1 |
| CBILI >1.5 ULN | 0 | 0 |
| Unconjugated Bilirubin >1.5 ULN | 21 | 22 |
| Unconjugated Bilirubin >2 ULN | 11 | 10 |
| ALT> 3 ULN and TBILI >2 ULN | 1 | 0 |
| CBILI >35% TBILI and TBILI >1.5 ULN | 0 | 0 |
| Albumin <=25 g/L | 0 | 0 |
Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 millimole/liter (mmol/L) and \<LLN; \>=11.1 mmol/L (unfasted \[unfas\]) or \>=7 mmol/L (fasted \[fas\]). * Hemoglobin A1c (HbA1c): \>8%. * Total cholesterol: \>=6.2 mmol/L; \>=7.74 mmol/L. * LDL cholesterol: \>=4.1 mmol/L; \>=4.9 mmol/L. * Triglycerides: \>=4.6 mmol/L; \>=5.6 mmol/L.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| Glucose <=3.9 mmol/L and <LLN | 10 | 8 |
| Glucose >=11.1 mmol/L (unfas) or >=7 mmol/L (fas) | 17 | 12 |
| HbA1c >8% | 3 | 3 |
| Total Cholesterol >=6.2 mmol/L | 52 | 88 |
| Total Cholesterol >=7.74 mmol/L | 15 | 14 |
| LDL Cholesterol >=4.1 mmol/L | 35 | 59 |
| LDL Cholesterol >=4.9 mmol/L | 18 | 20 |
| Triglycerides >=4.6 mmol/L | 4 | 8 |
| Triglycerides >=5.6 mmol/L | 3 | 6 |
Criteria for potentially clinically significant abnormalities: * Glucose: \<=3.9 mmol/L and \<LLN; \>=11.1 mmol/L (unfas) or \>=7 mmol/L (fas). * HbA1c: \>8%. * Total cholesterol: \>=6.2 mmol/L; \>=7.74 mmol/L. * LDL cholesterol: \>=4.1 mmol/L; \>=4.9 mmol/L. * Triglycerides: \>=4.6 mmol/L; \>=5.6 mmol/L.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| Glucose <=3.9 mmol/L and <LLN | 5 | 6 |
| Glucose >=11.1 mmol/L (unfas) or >=7 mmol/L (fas) | 20 | 14 |
| HbA1c >8% | 2 | 2 |
| Total Cholesterol >=6.2 mmol/L | 77 | 69 |
| Total Cholesterol >=7.74 mmol/L | 22 | 19 |
| LDL Cholesterol >=4.1 mmol/L | 57 | 48 |
| LDL Cholesterol >=4.9 mmol/L | 25 | 16 |
| Triglycerides >=4.6 mmol/L | 13 | 6 |
| Triglycerides >=5.6 mmol/L | 4 | 6 |
Number of participants with different post-baseline status of HDL: \< 40 mg/dL, 40 - \< 60 mg/dL, \>= 60 mg/dL, is reported here.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| HDL: < 40 mg/dL | 5 | 7 |
| HDL: 40 - < 60 mg/dL | 57 | 45 |
| HDL: >=60 mg/dL | 119 | 132 |
Number of participants with different post-baseline status of HDL: \< 40 mg/dL, 40 - \< 60 mg/dL, \>=60 mg/dL, is reported here.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| HDL: < 40 mg/dL | 7 | 5 |
| HDL: 40 - < 60 mg/dL | 52 | 49 |
| HDL: >=60 mg/dL | 94 | 111 |
Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromol/L (adults); \>=30% change from baseline, \>=100% change from baseline. * Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \<60 mL/min; \>=60 to \<90 mL/min. * Blood urea nitrogen: \>=17 mmol/L. * Uric acid: \<120 micromol/L; \>408 micromol/L.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| Creatinine >=150 micromol/L (Adults) | 0 | 3 |
| Creatinine >=30% change from baseline | 19 | 23 |
| Creatinine >=100% change from baseline | 0 | 1 |
| Creatinine Clearance <15 mL/min | 0 | 0 |
| Creatinine clearance >=15 to <30 mL/min | 0 | 1 |
| Creatinine clearance >=30 to <60 mL/min | 21 | 22 |
| Creatinine clearance >=60 to <90 mL/min | 74 | 65 |
| Blood Urea Nitrogen >=17 mmol/L | 0 | 2 |
| Uric acid <120 micromol/L | 4 | 3 |
| Uric acid >408 micromol/L | 25 | 35 |
Criteria for potentially clinically significant abnormalities: * Creatinine: \>=150 micromol/L (adults); \>=30% change from baseline, \>=100% change from baseline. * Creatinine clearance: \<15 mL/min; \>=15 to \<30 mL/min; \>=30 to \<60 mL/min; \>=60 to \<90 mL/min. * Blood urea nitrogen: \>=17 mmol/L. * Uric acid: \<120 micromol/L; \>408 micromol/L.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| Creatinine >=150 micromol/L (Adults) | 2 | 2 |
| Creatinine >=30% change from baseline | 63 | 62 |
| Creatinine >=100% change from baseline | 5 | 1 |
| Creatinine Clearance <15 mL/min | 0 | 0 |
| Creatinine clearance >=15 to <30 mL/min | 1 | 0 |
| Creatinine clearance >=30 to <60 mL/min | 34 | 24 |
| Creatinine clearance >=60 to <90 mL/min | 66 | 81 |
| Blood Urea Nitrogen >=17 mmol/L | 1 | 3 |
| Uric acid <120 micromol/L | 2 | 3 |
| Uric acid >408 micromol/L | 44 | 43 |
Criteria with potentially clinically significant urine abnormalities: pH: \<= 4.6; pH: \>= 8.0.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| pH <= 4.6 | 0 | 0 |
| pH >= 8.0 | 0 | 0 |
Criteria with potentially clinically significant urine abnormalities: pH: \<= 4.6; pH: \>= 8.0.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| pH <= 4.6 | 0 | 0 |
| pH >= 8.0 | 0 | 1 |
Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 mmol/L; \>=160 mmol/L. * Potassium: \<3 mmol/L; \>=5.5 mmol/L. * Chloride: \<80 mmol/L; \>115 mmol/L.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| Sodium <=129 mmol/L | 1 | 1 |
| Sodium >=160 mmol/L | 0 | 0 |
| Potassium <3 mmol/L | 3 | 0 |
| Potassium >=5.5 mmol/L | 0 | 0 |
| Chloride <80 mmol/L | 0 | 0 |
| Chloride >115 mmol/L | 0 | 1 |
Criteria for potentially clinically significant abnormalities: * Sodium: \<=129 mmol/L; \>=160 mmol/L. * Potassium: \<3 mmol/L; \>=5.5 mmol/L. * Chloride: \<80 mmol/L; \>115 mmol/L.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| Sodium <=129 mmol/L | 3 | 0 |
| Sodium >=160 mmol/L | 0 | 0 |
| Potassium <3 mmol/L | 2 | 2 |
| Potassium >=5.5 mmol/L | 6 | 7 |
| Chloride <80 mmol/L | 1 | 0 |
| Chloride >115 mmol/L | 0 | 0 |
Criteria for potentially clinically significant ECG abnormalities: * Heart rate (HR): \<50 beats per minute (bpm); \<50 bpm and DFB \>=20 bpm; \<40 bpm; \<40 bpm and DFB \>=20 bpm; \<30 bpm; \<30 bpm and DFB \>=20 bpm; \>90 bpm; \>=90 bpm and increase from baseline (IFB) \>=20 bpm; \>100 bpm; \>=100 bpm and IFB \>=20 bpm; \>120 bpm; \>=120 bpm and IFB \>=20 bpm. * PR Interval: \>200 millisecond (ms); \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25%. * QRS Interval: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25%. * QT Interval: \>500 ms. * QTc Bazett (QTc B): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms. * QTc Fridericia (QTc F): \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| HR <50 bpm | 4 | 5 |
| HR <50 bpm and DFB >=20 bpm | 0 | 0 |
| HR <40 bpm | 0 | 0 |
| HR <40 bpm and DFB >=20 bpm | 0 | 0 |
| HR <30 bpm | 0 | 0 |
| HR <30 bpm and DFB >=20 bpm | 0 | 0 |
| HR >90 bpm | 11 | 2 |
| HR >=90 bpm and IFB >=20 bpm | 5 | 1 |
| HR >100 bpm | 2 | 1 |
| HR >=100 bpm and IFB >=20 bpm | 2 | 0 |
| HR >120 bpm | 0 | 0 |
| HR >=120 bpm and IFB >=20 bpm | 0 | 0 |
| PR Interval >200 ms | 11 | 5 |
| PR Interval >200 ms and IFB >=25% | 1 | 0 |
| PR Interval >220 ms | 4 | 1 |
| PR Interval >220 ms and IFB >=25% | 0 | 0 |
| PR Interval >240 ms | 1 | 1 |
| PR Interval >240 ms and IFB >=25% | 0 | 0 |
| QRS Interval >110 ms | 3 | 9 |
| QRS Interval >110 ms and IFB >=25% | 0 | 0 |
| QRS Interval >120 ms | 1 | 2 |
| QRS Interval >120 ms and IFB >=25% | 0 | 0 |
| QT Interval >500 ms | 0 | 1 |
| QTc B >450 ms | 16 | 7 |
| QTc B >480 ms | 2 | 0 |
| QTc B >500 ms | 0 | 0 |
| QTc B IFB >30 and <=60 ms | 11 | 5 |
| QTc B IFB >60 ms | 0 | 0 |
| QTc F>450 ms | 7 | 5 |
| QTc F>480 ms | 0 | 0 |
| QTc F>500 ms | 0 | 0 |
| QTc F IFB >30 and <=60 ms | 9 | 3 |
| QTc F IFB >60 ms | 0 | 0 |
Criteria for potentially clinically significant ECG abnormalities: * HR: \<50 bpm; \<50 bpm and DFB \>=20 bpm; \<40 bpm; \<40 bpm and DFB \>=20 bpm; \<30 bpm; \<30 bpm and DFB \>=20 bpm; \>90 bpm; \>=90 bpm and IFB \>=20 bpm; \>100 bpm; \>=100 bpm and IFB \>=20 bpm; \>120 bpm; \>=120 bpm and IFB \>=20 bpm. * PR Interval: \>200 ms; \>200 ms and IFB \>=25%; \>220 ms; \>220 ms and IFB \>=25%; \>240 ms; \>240 ms and IFB \>=25%. * QRS Interval: \>110 ms; \>110 ms and IFB \>=25%; \>120 ms; \>120 ms and IFB \>=25%. * QT Interval: \>500 ms. * QTc B: \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms. * QTc F: \>450 ms; \>480 ms; \>500 ms; IFB \>30 and \<=60 ms; IFB \>60 ms.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| HR <50 bpm | 10 | 19 |
| HR <50 bpm and DFB >=20 bpm | 0 | 3 |
| HR <40 bpm | 1 | 1 |
| HR <40 bpm and DFB >=20 bpm | 0 | 1 |
| HR <30 bpm | 0 | 0 |
| HR <30 bpm and DFB >=20 bpm | 0 | 0 |
| HR >90 bpm | 16 | 11 |
| HR >=90 bpm and IFB >=20 bpm | 7 | 6 |
| HR >100 bpm | 3 | 3 |
| HR >=100 bpm and IFB >=20 bpm | 2 | 1 |
| HR >120 bpm | 0 | 0 |
| HR >=120 bpm and IFB >=20 bpm | 0 | 0 |
| PR Interval >200 ms | 17 | 14 |
| PR Interval >200 ms and IFB >=25% | 6 | 3 |
| PR Interval >220 ms | 8 | 6 |
| PR Interval >220 ms and IFB >=25% | 4 | 3 |
| PR Interval >240 ms | 2 | 2 |
| PR Interval >240 ms and IFB >=25% | 2 | 1 |
| QRS Interval >110 ms | 8 | 18 |
| QRS Interval >110 ms and IFB >=25% | 2 | 1 |
| QRS Interval >120 ms | 3 | 7 |
| QRS Interval >120 ms and IFB >=25% | 1 | 0 |
| QT Interval >500 ms | 2 | 2 |
| QTc B >450 ms | 35 | 33 |
| QTc B >480 ms | 3 | 30 |
| QTc B >500 ms | 1 | 1 |
| QTc B IFB >30 and <=60 ms | 18 | 23 |
| QTc B IFB >60 ms | 3 | 2 |
| QTc F>450 ms | 16 | 16 |
| QTc F>480 ms | 3 | 2 |
| QTc F>500 ms | 0 | 1 |
| QTc F IFB >30 and <=60 ms | 19 | 19 |
| QTc F IFB >60 ms | 4 | 3 |
Criteria for potentially clinically significant vital sign abnormalities: Systolic blood pressure (SBP) supine: \<=95 mmHg and DFB\>=20 mmHg; \>=160 mmHg and IFB \>=20 mmHg. Diastolic blood pressure (DBP) supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg. SBP (Orthostatic): \<=-20 mmHg. DBP (Orthostatic): \<=-10 mmHg. HR supine: \<=50 bpm and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm. Weight: \>=5% DFB; \>=5% IFB.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| SBP (supine) <=95 mmHg and DFB >=20 mmHg | 4 | 3 |
| SBP (supine) >=160 mmHg and IFB >=20 mmHg | 4 | 5 |
| DBP (supine) <=45 mmHg and DFB >=10 mmHg | 1 | 1 |
| DBP (supine) >=110 mmHg and IFB >=10 mmHg | 1 | 1 |
| SBP (orthostatic) <=-20 mmHg | 13 | 10 |
| DBP (orthostatic) <=-10 mmHg | 20 | 27 |
| HR (supine) <=50 bpm and DFB >= 20 bpm | 2 | 1 |
| HR (supine) >=120 bpm and IFB >=20 bpm | 1 | 0 |
| Weight >=5% DFB | 12 | 6 |
| Weight >=5% IFB | 21 | 23 |
Criteria for potentially clinically significant vital sign abnormalities: SBP supine: \<=95 mmHg and DFB \>=20 mmHg; \>=160 mmHg and IFB \>=20 mmHg. DBP supine: \<=45 mmHg and DFB \>=10 mmHg; \>=110 mmHg and IFB \>=10 mmHg. SBP (Orthostatic): \<=-20 mmHg. DBP (Orthostatic): \<=-10 mmHg. HR supine: \<=50 bpm and DFB \>=20 bpm; \>=120 bpm and IFB \>=20 bpm. Weight: \>=5% DFB; \>=5% IFB.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| SBP (supine) <=95 mmHg and DFB >=20 mmHg | 3 | 9 |
| SBP (supine) >=160 mmHg and IFB >=20 mmHg | 10 | 11 |
| DBP (supine) <=45 mmHg and DFB >=10 mmHg | 0 | 0 |
| DBP (supine) >=110 mmHg and IFB >=10 mmHg | 1 | 2 |
| SBP (orthostatic) <=-20 mmHg | 24 | 32 |
| DBP (orthostatic) <=-10 mmHg | 41 | 46 |
| HR (supine) <=50 bpm and DFB >= 20 bpm | 3 | 0 |
| HR (supine) >=120 bpm and IFB >=20 bpm | 0 | 0 |
| Weight >=5% DFB | 44 | 51 |
| Weight >=5% IFB | 82 | 87 |
Anti-drug antibody response was categorized as: Treatment emergent and Treatment-boosted. Treatment emergent ADAs was defined as a participant with no positive assay response at baseline but with a positive assay response during the TEAE period. Treatment boosted ADAs: defined as participants with a positive ADA assay response at baseline and with at least a 4-fold increase in titer compared to baseline during the TEAE period. TEAE period: time from first dose of study drug up to day before first dose of open-label treatment for participants who completed 24-week randomized/DB treatment.
| Participants | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|
| Treatment-emergent ADA | 13 |
| Treatment-boosted ADA | 0 |
Anti-drug antibody response was categorized as: Treatment emergent and Treatment-boosted. Treatment emergent ADAs was defined as a participant with no positive assay response at baseline but with a positive assay response during the entire TEAE period. Treatment boosted ADAs: defined as participants with a positive ADA assay response at baseline and with at least a 4-fold increase in titer compared to baseline during the entire TEAE period. Entire TEAE period: last OLE dose - first DB dose date + 6 weeks (follow-up), regardless of unplanned intermittent discontinuations.
| Participants | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| Treatment-emergent ADAs | 11 | 11 |
| Treatment-boosted ADAs | 0 | 0 |
Data for this outcome measure was not planned to be collected and analyzed for "Adalimumab 40 mg/Sarilumab 200 mg" arm.
| nanograms per milliliter (ng/mL) | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|
| Baseline | 0.00 ± 0.00 |
| Week 2 | 5566.03 ± 4843.57 |
| Week 4 | 11209.64 ± 8202.70 |
| Week 12 | 21355.19 ± 14805.63 |
| Week 16 | 23143.39 ± 16508.71 |
| Week 20 | 25252.43 ± 17319.04 |
| Week 24 | 24233.10 ± 17581.72 |
| ng/mL | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg |
|---|---|---|
| Week 24 (Baseline of OLE period) | 109.38 ± 1237.44 | 24403.72 ± 17588.31 |
| Week 36 | 18952.69 ± 15125.86 | 26006.07 ± 19194.79 |
| Week 48 | 21911.87 ± 17926.01 | 25571.16 ± 18958.00 |
| Week 60 | 21583.82 ± 17594.87 | 24005.78 ± 18541.46 |
| Week 84 | 23230.92 ± 18274.09 | 23873.23 ± 19794.57 |
| Week 108 | 20405.02 ± 15553.02 | 21023.55 ± 17792.89 |
| Week 132 | 20814.89 ± 17848.70 | 20021.53 ± 18580.91 |
| Week 156 | 23604.11 ± 19660.31 | 22423.29 ± 18757.11 |
| Week 180 | 18611.01 ± 16417.46 | 21856.85 ± 18612.43 |
| Week 204 | 17982.66 ± 16640.61 | 18244.96 ± 16383.47 |
| Week 228 | 19451.40 ± 17694.09 | 18315.19 ± 17525.62 |
| Week 252 | 19663.10 ± 16020.11 | 19224.47 ± 16964.41 |
| Week 276 | 19071.00 ± 18425.13 | 17014.75 ± 16207.18 |
| Week 300 | — | 9260.00 ± 8683.27 |
| Week 306 (Follow-up) | 1237.01 ± 2856.88 | 2280.98 ± 7909.71 |
Collected over All Adverse Events (AEs) were collected from up to Week 24 in DB period and from end of Week 24 (Baseline of OLE Period) up to Week 306 in OLE Period regardless of seriousness or relationship to study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB Period - Adalimumab 40 mg | 0/184 (0%) | 13/184 (7.1%) | 62/184 (33.7%) |
| DB Period - Sarilumab 200 mg | 1/184 (0.5%) | 9/184 (4.9%) | 79/184 (42.9%) |
| OLE Period - Sarilumab 200 mg | 8/320 (2.5%) | 56/320 (17.5%) | 220/320 (68.8%) |
| Event | DB Period - Adalimumab 40 mg | DB Period - Sarilumab 200 mg | OLE Period - Sarilumab 200 mg |
|---|---|---|---|
| PneumoniaInfections and infestations | 0/184 | 0/184 | 5/320 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/184 | 0/184 | 5/320 |
| CholelithiasisHepatobiliary disorders | 0/184 | 0/184 | 4/320 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/184 | 0/184 | 3/320 |
| AnaemiaBlood and lymphatic system disorders | 0/184 | 0/184 | 2/320 |
| CataractEye disorders | 0/184 | 0/184 | 2/320 |
| Pancreatitis acuteGastrointestinal disorders | 0/184 | 0/184 | 2/320 |
| Arthritis bacterialInfections and infestations | 1/184 | 0/184 | 0/320 |
| Bursitis infectiveInfections and infestations | 0/184 | 1/184 | 0/320 |
| MastitisInfections and infestations | 0/184 | 1/184 | 0/320 |
| Event | DB Period - Adalimumab 40 mg | DB Period - Sarilumab 200 mg | OLE Period - Sarilumab 200 mg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 14/184 | 11/184 | 60/320 |
| NeutropeniaBlood and lymphatic system disorders | 1/184 | 25/184 | 59/320 |
| BronchitisInfections and infestations | 7/184 | 12/184 | 41/320 |
| Accidental overdoseInjury, poisoning and procedural complications | 11/184 | 5/184 | 39/320 |
| Upper respiratory tract infectionInfections and infestations | 7/184 | 3/184 | 36/320 |
| Urinary tract infectionInfections and infestations | 4/184 | 5/184 | 30/320 |
| HypertensionVascular disorders | 3/184 | 4/184 | 28/320 |
| Injection site erythemaGeneral disorders | 7/184 | 14/184 | 26/320 |
| Alanine aminotransferase increasedInvestigations | 6/184 | 7/184 | 23/320 |
| Back painMusculoskeletal and connective tissue disorders | 3/184 | 3/184 | 21/320 |
Analysis was performed on randomized population that included all participants who received at least 1 dose or part of a dose of Investigational Medicinal Product (IMP).
| Age, Continuous(years) | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg | Total |
|---|---|---|---|
| Mean | 53.6 ± 11.9 | 50.9 ± 12.6 | 52.2 ± 12.3 |
| Sex: Female, Male(Participants) | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg | Total |
|---|---|---|---|
| Female | 150 | 157 | 307 |
| Male | 35 | 27 | 62 |
| Race/Ethnicity, Customized(Participants) | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg | Total |
|---|---|---|---|
| Caucasian/White | 164 | 171 | 335 |
| Black | 3 | 1 | 4 |
| Asian/Oriental | 9 | 2 | 11 |
| Other | 9 | 10 | 19 |
| Disease Activity Score 28 based on erythrocyte sedimentation rate (DAS28-ESR)(units on a scale) | Adalimumab 40 mg/Sarilumab 200 mg | Sarilumab 200 mg/Sarilumab 200 mg | Total |
|---|---|---|---|
| Mean | 6.76 ± 0.83 | 6.83 ± 0.76 | 6.80 ± 0.80 |
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jan 2015 to primary completion in Jan 2016, 11 months.
Results were first posted in Jul 2017, 1 year 6 months after primary completion. A results delay was requested in Dec 2016.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 11 months is below that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sarilumab